News ViiV's bimonthly HIV PrEP jab cleared for use by NHS ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.
News Gilead poised to bring twice-yearly HIV PrEP to EU Gilead gets EU approval for its twice-yearly PrEP product Yeytuo, another key step in building what it hopes will be a new HIV blockbuster.
News Gilead's twice-yearly HIV PrEP set for wider rollout The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
News FDA sets June date for Gilead's twice-yearly HIV PrEP Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.
News Gilead emerges victorious from HIV PrEP patent trial A US court has sided with Gilead Sciences in a dispute with the US government centred on the use of HIV medicines for pre-exposure prophylaxis.
News NHS staff 'feel unprepared for digital transformation' A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
